menu
    • menu
    [{"orgOrder":0,"company":"Shanghai Mental Health Center","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Clozapine","moa":"Serotonin 2a (5-HT2a) receptor | Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"Shanghai Mental Health Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Mental Health Center \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Shanghai Mental Health Center \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Mental Health Center","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Clozapine","moa":"Serotonin 2a (5-HT2a) receptor | Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Shanghai Mental Health Center","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Mental Health Center \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Mental Health Center \/ Undisclosed"},{"orgOrder":0,"company":"Whanin Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Clozapine","moa":"Serotonin 2a (5-HT2a) receptor | Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Whanin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Whanin Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Whanin Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Mental Health Services in the Capital Region, Denmark","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Clozapine","moa":"Serotonin 2a (5-HT2a) receptor | Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"Mental Health Services in the Capital Region, Denmark","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mental Health Services in the Capital Region, Denmark \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Mental Health Services in the Capital Region, Denmark \/ Undisclosed"},{"orgOrder":0,"company":"Tirat Carmel Mental Health Center","sponsor":"Technion \u2013 Israel Institute of Technology | Ben-Gurion University of the Negev | Beersheva Mental Health Center | Sha'ar Menashe Mental Health Center | HaEmek Medical Center, Israel | The Nazareth Hospital, Israel","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Clozapine","moa":"Serotonin 2a (5-HT2a) receptor | Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"Tirat Carmel Mental Health Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tirat Carmel Mental Health Center \/ Technion \u2013 Israel Institute of Technology | Ben-Gurion University of the Negev | Beersheva Mental Health Center | Sha'ar Menashe Mental Health Center | HaEmek Medical Center, Israel | The Nazareth Hospital, Israel","highestDevelopmentStatusID":"11","companyTruncated":"Tirat Carmel Mental Health Center \/ Technion \u2013 Israel Institute of Technology | Ben-Gurion University of the Negev | Beersheva Mental Health Center | Sha'ar Menashe Mental Health Center | HaEmek Medical Center, Israel | The Nazareth Hospital, Israel"},{"orgOrder":0,"company":"Geha Mental Health Center","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Clozapine","moa":"Serotonin 2a (5-HT2a) receptor | Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Geha Mental Health Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Geha Mental Health Center \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Geha Mental Health Center \/ Undisclosed"},{"orgOrder":0,"company":"Centre for Addiction and Mental Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Clozapine","moa":"Serotonin 2a (5-HT2a) receptor | Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"Centre for Addiction and Mental Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centre for Addiction and Mental Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Centre for Addiction and Mental Health \/ Undisclosed"},{"orgOrder":0,"company":"Centre for Addiction and Mental Health","sponsor":"The Ian Douglas Bebensee Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Clozapine","moa":"Serotonin 2a (5-HT2a) receptor | Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"Centre for Addiction and Mental Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centre for Addiction and Mental Health \/ The Ian Douglas Bebensee Foundation","highestDevelopmentStatusID":"11","companyTruncated":"Centre for Addiction and Mental Health \/ The Ian Douglas Bebensee Foundation"},{"orgOrder":0,"company":"Tanner Pharma","sponsor":"Extractas Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Agreement","leadProduct":"Clozapine","moa":"Serotonin 2a (5-HT2a) receptor | Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Tanner Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tanner Pharma \/ Tasmanian Alkaloids Pty Ltd","highestDevelopmentStatusID":"15","companyTruncated":"Tanner Pharma \/ Tasmanian Alkaloids Pty Ltd"}]

    Find Clinical Drug Pipeline Developments & Deals for clozapine(tautomer)

    Menu

    clozapine(tautomer)

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Mental Health Services in the Capital Region, Denmark

                            Country arrow
                            IPEX Indonesia
                            Not Confirmed

                            Mental Health Services in the Capital Region, Denmark

                            Country arrow
                            IPEX Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Clozapine

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Biomarkers in Clozapine-responding Schizophrenia

                            Details : Clozapine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Schizophrenia.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 07, 2022

                            Lead Product(s) : Clozapine

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Whanin Pharmaceutical

                            South Korea arrow
                            IPEX Indonesia
                            Not Confirmed

                            Whanin Pharmaceutical

                            South Korea arrow
                            IPEX Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Clozapine

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bioequivalence Study in Patients With Schizophrenia by Using Clozaril 100 mg Tablet (Clozapine) and WID-CLZ18

                            Details : Clozaril (Clozapine) is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Schizophrenia.

                            Product Name : Clozaril

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 19, 2021

                            Lead Product(s) : Clozapine

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Shanghai Mental Health Center

                            Country arrow
                            AllPack Indonesia
                            Not Confirmed

                            Shanghai Mental Health Center

                            Country arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Clozapine

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            SMART Design to Compare Antipsychotic Treatments in Treatment-Resistant Schizophrenia

                            Details : Clozapine is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Schizophrenia, Treatment-Resistant.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 27, 2020

                            Lead Product(s) : Clozapine

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Tanner Pharma

                            U.S.A arrow
                            IPEX Indonesia
                            Not Confirmed

                            Tanner Pharma

                            U.S.A arrow
                            IPEX Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Clozapine

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Approved FDF

                            Sponsor : Extractas Bioscience

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Tanner Pharma Group Signs Versacloz Distribution Agreement with Tasman Pharma Inc.

                            Details : Tanner to distribute Versacloz in areas outside of the U.S where the product is not yet registered. Versacloz is indicated for the treatment of severely ill patients with schizophrenia who fail to respond to standard antipsychotic treatment.

                            Product Name : Versacloz

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            June 22, 2020

                            Lead Product(s) : Clozapine

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Approved FDF

                            Sponsor : Extractas Bioscience

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Shanghai Mental Health Center

                            Country arrow
                            AllPack Indonesia
                            Not Confirmed

                            Shanghai Mental Health Center

                            Country arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Clozapine

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Efficacy of Computerized Cognitive Remediation Therapy for Chronic Schizophrenia

                            Details : Clozapine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Schizophrenia.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 12, 2018

                            Lead Product(s) : Clozapine

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Centre for Addiction and Mental Health

                            Country arrow
                            IPEX Indonesia
                            Not Confirmed

                            Centre for Addiction and Mental Health

                            Country arrow
                            IPEX Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Clozapine

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase IV

                            Sponsor : The Ian Douglas Bebensee Foundation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Switching Antipsychotics: Abrupt Discontinuation Versus Overlap

                            Details : Clozapine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Schizophrenia.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 28, 2015

                            Lead Product(s) : Clozapine

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase IV

                            Sponsor : The Ian Douglas Bebensee Foundation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Centre for Addiction and Mental Health

                            Country arrow
                            IPEX Indonesia
                            Not Confirmed

                            Centre for Addiction and Mental Health

                            Country arrow
                            IPEX Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Clozapine

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Switching From Twice-Daily to Once-Daily Clozapine Dosing in Schizophrenia

                            Details : Clozapine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Schizophrenia.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 24, 2015

                            Lead Product(s) : Clozapine

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Tirat Carmel Mental Health Center

                            Country arrow
                            IPEX Indonesia
                            Not Confirmed

                            Tirat Carmel Mental Health Center

                            Country arrow
                            IPEX Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Clozapine

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase IV

                            Sponsor : Technion – Israel Institute of Technology | Ben-Gurion University of the Negev | Beersheva Mental Health Center | Sha'ar Menashe Mental Health Center | HaEmek Medical Center, Israel | The Nazareth Hospital, Israel

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Clozapine Plasma Levels and the Relationship to the Genetic Polymorphism in Shizophrenic Patients

                            Details : Clozapine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Schizophrenia.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 13, 2012

                            Lead Product(s) : Clozapine

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase IV

                            Sponsor : Technion – Israel Institute of Technology | Ben-Gurion University of the Negev | Beersheva Mental Health Center | Sha'ar Menashe Mental Health Center | HaEmek Medical Center, Israel | The Nazareth Hospital, Israel

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Geha Mental Health Center

                            Country arrow
                            IPEX Indonesia
                            Not Confirmed

                            Geha Mental Health Center

                            Country arrow
                            IPEX Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Clozapine

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Clozapine Versus Amisulpride in Treatment-resistant Schizophrenia Patients

                            Details : Clozapine is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Schizophrenia.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 07, 2011

                            Lead Product(s) : Clozapine

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth